Chronic heart failure (HF) is a major cause of mortality and morbidity. HF is associated with a hypercoagulable state, left ventricular thrombus formation, and cerebral embolism.
1,2 It is also associated with both sudden death and death resulting from progressive HF that may be caused by unrecognized atherothrombotic events. 3 This provides a rationale for the use of oral anticoagulants to treat patients with chronic HF.
The Warfarin vs. Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial found no significant difference between warfarin and aspirin among HF patients for the primary endpoint of first to occur of ischemic stroke, intracerebral hemorrhage, or death, although there was a large reduction in ischemic stroke in the warfarin group. 4 HF patients are diverse in terms of demographics, etiology of HF, symptomatology, and many other factors. [4] [5] [6] Patients in various groups may respond differently to warfarin or aspirin, and there is a great interest in this issue. 7, 8 As such, we sought to explore if there are readily identifiable subgroups for whom warfarin or aspirin is preferable, without compromise from increased risk of major bleeding. We chose to consider multiple baseline clinical factors, both individually and in combination, since many of them are closely interrelated and can not be considered in isolation. To our knowledge, this is the first study able to assess this issue with a large and comprehensive data base.
Methods

Patients
In the randomized, double-blind WARCEF trial (http://www.ClinicalTrials.gov No.
NCT00041938), patients with left ventricular ejection fraction (LVEF) 35% in sinus rhythm
were randomly assigned to warfarin (target INR 2.75, with acceptable target range of 2.0 to 3.5)
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October 2002 and January 2010. The study was approved by Institutional Review Boards at the coordinating centers of all sites, and all subjects gave informed consent. The median follow-up time was 3.4 years (Q1;2.0, Q3;5.0). LVEF was assessed by quantitative echocardiography (or a wall-motion index of 1.2), or radionuclide contrast ventriculography within 3 months before randomization. Patients who had a clear indication for warfarin or aspirin were not eligible.
Additional eligibility criteria were a modified Rankin score of 4 or less (on a scale of 0 to 6, with higher scores indicating more severe disability), and planned treatment with a beta-blocker, an angiotensin-converting enzyme (ACE) inhibitor (or, if the side-effect profile with ACE inhibitors was unacceptable, with an angiotensin-receptor blocker), or hydralazine and nitrates. Patients were ineligible if they had a condition that conferred a high risk of cardiac embolism, such as atrial fibrillation, a mechanical cardiac valve, endocarditis, or an intracardiac mobile or pedunculated thrombus.
Randomization and Outcome Events
Patients were randomly assigned (1:1) to warfarin or aspirin by a 24 hour central computerized system. Randomization was stratified according to whether or not patients had an ischemic stroke or TIA within 12 months before randomization; NYHA classification (I vs. II, III, or IV);
and clinical site. Participants, investigators, and the sponsor were masked to individual participant treatment assignments. The Statistical Analysis Center (SAC) fabricated clinically plausible INR results for patients in the aspirin group and provided these results to the sites, along with the actual INR results for the patients in the warfarin group. All patients were treated as if they were receiving active warfarin.
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Statistical Analysis
Subgroup Candidates
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Results
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patients, there was no difference between warfarin and aspirin (adjusted HR 1.09, CI 0.88-1.35, p=0.44) ( Table 2 ). Figure 1A shows the unstratified cumulative incidence curves for the primary endpoint for the younger and older age groups respectively.
We evaluated our age cutoff (<60 years) by modeling age as a continuous variable and by comparing warfarin and aspirin by age quintile. There was a significant interaction between treatment and continuous age as a linear effect on the log HR (p=0.04 when adjusting for covariates from the final selected model) (table not presented). According to this model, there was a significant benefit for warfarin among younger patients. The upper limit of the 95% CI crossed 1.0 at 59.4 years, and there was no significant treatment effect among patients older than 60. When warfarin and aspirin were compared in age quintiles, there was a statistically significant interaction between treatment and age quintile (p=0.04). Figure 2A presents the HRs for treatment effect by quintile, and supports 60 years as a reasonable cutoff.
Components of the Primary Outcome
The ischemic stroke rates in younger and older patients were similar, and in both age groups those assigned to warfarin achieved a substantial reduction in ischemic stroke compared to aspirin (HR 0.51, CI 0.32-0.81, p for HR 0.005, p for interaction 0.64) ( In the younger age group, there was no significant difference between warfarin and aspirin in the rate of major hemorrhages (odds ratio 1.30, CI 0.56-3.07, p=0.64). However, in the older age group, significantly more major hemorrhages occurred in those receiving warfarin (odds ratio 2.73, CI 1.56-4.97, p<0.001) ( Table 3 ). When the time to first to occur of primary outcome or major hemorrhage was analyzed, there was a statistically significant treatment-by-age group interaction with respect to this composite outcome (p<0.001) ( Table 4) . Among the younger patients, those randomized to warfarin had a lower rate of combined events compared to aspirin patients (5.41 vs. 7.25% per 100 patient years; adjusted HR 0.68, CI 0.52-0.89, p=0.005), whereas older patients in the warfarin arm experienced a significantly higher rate of events than those in the aspirin arm (11.8 vs. 9 .35% per 100 patient years; adjusted HR 1.25, 95% CI 1.02-1.53, p=0.03) ( Table 4 ). Figure 1B presents the unstratified cumulative incidence curves, and Figure 2B the HRs by age quintile, both by treatment, when major hemorrhage is included in the outcome.
Patient Characteristics by Age
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Discussion
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characteristics and identify treatment-by-variable interactions for multiple variables that may covary.
Country of recruitment significantly affected the efficacy of warfarin or aspirin, but this was because of country differences in age distribution. After adjustment for all factors considered, age group was the only modifier of treatment effect. Warfarin patients younger than 60 experienced a significant reduction in the rate of composite primary endpoint, and also in its separate components of ischemic stroke and death, without an increase in major bleeding. Older patients, in contrast, experienced no difference between warfarin and aspirin in the composite primary endpoint. Warfarin did reduce their ischemic stroke risk, but it was also associated with a non-significant increase in death; and when major bleeding was added to the composite outcome, the overall risk of a poor outcome became significantly greater for the older warfarin patients. The reduced benefit of warfarin in older patients compared to younger patients is not attributable to lower INRs or a lower TTR. In fact, the older group demonstrated significantly higher TTR and less time spent above therapeutic INR while having similar time duration spent in IOT compared with the younger group.
There are approximately 5.7 million HF patients in the US and 25% are aged under 60. 14, 15 Of this group, up to 60% or 855,000 are thought to have systolic rather than diastolic HF. 16, 17 Among this group, since the prevalence of atrial fibrillation is smaller in younger patients with HF, 90% or 769,500 patients are in sinus rhythm. 18 In our study, in the younger population, the absolute yearly risk reduction was 1.95% (relative risk reduction of 28.8%) which would mean approximately 15,005 net events (5,617 strokes and 10,157 deaths at a cost of 769 ICHs) may possibly be avoided by the use of warfarin in younger patients. On the other hand, in the older population, since warfarin resulted in increased bleeding risk while not , but it was also so so so so so so l r r r r ris is is is i k of a a a p p p p poo oo oo oo oor r r r r ou ou ou ou outc c c c com om om om ome e e e e be be b beca ca c c c me e e sign gn gn gn gnif if if if ific c c c can an an a antl tl tl l ly y y y y gr r r rea ea ea ea eate te te te ter r r r r fo fo fo fo for r r r r th th th th the d be be be be bene ne ne ne n fi fi fi fi fit t t t of of of of of wa wa wa wa warf rf r r ar r r r rin in in in in i i i i in ol ol ol ol olde de de de der r r r r pa pa pa pa p ti ti ti t t en en en en ents ts ts ts ts c c c c com om om om ompa pa pa pa par r r r red ed ed d d t t t t to o o o o yo yo y y y un un un un unge ge ge e ger r r r r p r r r IN IN INRs Rs Rs o o or r r a a a lo lo lowe we wer r r TT TT TTR R R. I I In n n fa fa fact ct ct, th th the e e ol ol olde de der r r gr gr gr g g ou ou oup p p p de de dem m mon on onst st stra ra rate te ted d d affecting the primary endpoint, unnecessary bleeding may be avoided by the use of aspirin. We saw a longer time on IOT amongst older patients assigned to warfarin. This may have blunted any possible benefit of warfarin and points to difficulty of warfarin use in older patients. 19, 20 Although our findings may have a large public health impact, they require confirmation in a future trial. Also, given the possible benefit of warfarin in the younger population, the role of new anticoagulants needs to be established. Younger patients may benefit from the ease of use of these agents, and older patients may have a lower bleeding risk while maintaining the benefit for stroke reduction. 21, 22 In WARCEF, patients were double-blindly randomized, lost to follow-up rate was low, and core echocardiography laboratory as well as centralized adjudication process were used to achieve high data quality. However, there are important limitations. First, candidate variables included those that were not pre-specified although they are well known or thought to affect the outcome in HF patients. Second, no correction for the number of variables examined was made.
However, under a simple Bonferroni correction for the 32 variables considered in Stage 1, the effect modification for age was significant. Third, no placebo group was included. Therefore, the comparison is strictly between those receiving warfarin and aspirin. Finally, while we can point to potential mechanisms, we have no clear biological explanation for our results.
Conclusion
In our exploratory analysis, HF patients in sinus rhythm aged less than 60 benefited from warfarin compared to aspirin on the combined outcome of ischemic stroke, intracerebral hemorrhage, or death, while older patients did not. When major hemorrhages are also considered, the warfarin benefit for the younger patients persisted, but older patients on warfarin ost to follow u u u u u u up p dica a a a a a ati ti ti ti ti tion on on on on on on p p p p p p pro ro ro ro ro ro roce ce ce ce ce ce cess s uality. However, there are important limitations. First, cand d w g e m ual al al al ali i it i i y. H H H H How ow ow ow wev ev ev ev ever er er er er, , , , , th th th th ther er er er ere e e e e ar ar ar ar are e e im im im m mpo o port tan n n n nt t t t t li li li li limi mi mi mi mita ta ta ta t ti ti ti i ion on on on ons. F F F F Fir ir ir ir irst s s s s , , , ca ca ca ca cand nd nd nd ndid
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The differences between warfarin and aspirin were significant at the alpha=0.05 level for six minute walk distance (p=0.020) and nitrate use (p=0.012). 
